bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, announces the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”). With the closing of the transaction, bluebird’s common stock has ceased trading and will no longer be publicly listed. Carlyle and SK Capital have provided significant primary capital to support and scale bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
Read the full article: bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital //
Source: https://www.businesswire.com/news/home/20250602288470/en/bluebird-bio-Announces-Completion-of-Acquisition-by-Carlyle-and-SK-Capital